丙氨瑞林缓释剂对子宫内膜异位症的实验与临床研究  

Experimental and clinical study on the effect of sustained-releasing injection of Alarelin on endometriosis

作　　者：赵瑞钦[1] 瞿文[2] 张菊新[1] 陈庆华[2] 周美华[3] 

机构地区：[1]河南省人民医院妇产科,河南郑州450003 [2]上海市医药工业研究院制剂室,上海200000 [3]上海复旦大学医学院基础医学院药理教研室,上海200433

出　　处：《河南医学研究》2002年第2期118-121,共4页Henan Medical Research

摘　　要：目的 :观察促性腺激素释放激素 (LHRH)类似物丙氨瑞林缓释剂 (Alarelin ,Ala)对大鼠移植性异位子宫内膜的抑制作用和对子宫内膜异位症的疗效。方法 :用外科自体移植术建立大鼠子宫内膜异位症动物模型 ,并以未给药组和去势组作对照组。依典型症状、子宫直肠陷凹硬结节体积和触痛程度、B超发现巧克力囊肿等进行子宫内膜异位症的诊断并进行随机分组。上述各组分别给以不同剂量的Ala缓释剂 ,时间分别为 4周和 12周。结果 :Ala缓释剂对大鼠异位子宫内膜有明显的抑制作用 ,使异位内膜停止生长、使其萎缩或消失 ,可达“药物性去卵巢”的作用效果 ,使人产生低雌激素状态 ,对子宫内膜异位症有明显的疗效 ,其作用持续时间长 ,未发现明显的副作用。结论 :Ala缓释剂对子宫内膜异位症有明显的治疗作用 ,有很好的临床应用前景。Objective: To study the inhibitory effect of alarelin(Ala) sustained-releasing injection on the growth of endometrial explants in rats model of endometriosis and the therapeutical effect on endometriosis.Methods: The model of endometriosis in rats was made by surgically autotransplanting endometrium to the peritoneum and control groups were castration group and non-administered group. And diagnosis criteria of endometriosis depended on typical symptom, node's volume and pain extent and discovery of B ultrasound. All groups were administered alarelin 4 weeks and 12 weeks respectively. Evaluating criteria respectively depended on change of ectopic endometrium volume and alleviation of symptom and improvement of health.Results: The result showed that chronic administration of sustained-releasing injection of alarelin for 4 weeks produced obvious inhibitory effect on the growth of endometrial explants in rats. The inhibitory effect might be equal to that of ovariotomy. And there was alleviation of symptom and improvement of health in patient with endometriosis. At the same time, an obvious depression in serum estradiol level occurred. There were hardly side action seen. Conclusion: There was obvious therapautical effect of sustained-releasing injection of alarelin on endometriosis and there is a good future.

关 键 词：丙氨瑞林缓释剂 实验 临床研究 促性腺激素释放激素类似物 子宫内膜异位症 缓释剂 

分 类 号：R711.71[医药卫生—妇产科学]